LUNSUMIO injection Drug Use Surveillance (Relapsed or Refractory Follicular Lymphoma)

LUNSUMIO injection Drug Use Surveillance (Relapsed or Refractory Follicular Lymphoma) - LUNSUMIO injection Drug Use Surveillance (Relapsed or Refractory Follicular Lymphoma)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057474

Enrollment

120

Registered

2025-04-01

Start date

2025-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The objective is to explore risk factors for cytokine release syndrome (CRS) under the actual use status of Lunsumio intravenous infusion (Hereinafter referred to as this drug) for relapsed or refractory follicular lymphoma.

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects to be registered: Patients with relapsed or refractory follicular lymphoma who are scheduled to use this drug for the first time or who use this drug for the first time at the institutions with which a contract for this survey has been concluded, and whose number of consecutive patients reached the number of contracted cases from the date of initial marketing in Japan. Subjects for whom survey forms are collected: Patients who used this drug among subjects to be registered.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
CRS Risk Factors	—

Countries

Japan

Contacts

Public ContactAyako Murayama

Chugai Pharmaceutical Co. Ltd Safety Science 2 Department

murayamaayk@chugai-pharm.co.jp03-3281-6611

Outcome results